Highest-materiality recent filing
InfuSystem announces $20M stock repurchase program beginning July 1, 2026
Board approved $20M stock repurchase program, starting July 1, 2026 through June 30, 2028.
InfuSystem Holdings elects Beverly Huss as Chairman of the Board
Beverly Huss appointed Chairman effective May 11, 2026 following annual meeting.
InfuSystem stockholders approve equity plan amendment raising share reserve to 7M
Stockholders approved Third Amendment to 2021 Equity Plan, increasing authorized shares to 7,000,000, enabling further equity awards.
InfuSystem Q1 net rev $33.7M (-3% YoY); net income $1.0M vs prior loss
Patient Services rev $22.1M (+6% YoY); wound care revenue more than doubled to $2.1M.
InfuSystem to report Q1 2026 results on May 7, 2026
Earnings release before market open on Thursday, May 7, 2026.
InfuSystem dismisses Deloitte, appoints Grant Thornton as auditor for FY 2026
Audit Committee dismissed Deloitte & Touche LLP on March 13, 2026 after competitive selection process.
InfuSystem to present at 38th Annual ROTH Conference on March 23, 2026
CEO Carrie Lachance and CFO Barry Steele will attend the ROTH Conference on March 23, 2026.
InfuSystem reports record 2025 revenue $143.4M, adj. EBITDA $31.5M, net leverage 0.52x
2025 net revenue $143.4M, up 6.3% YoY from $134.9M; seven consecutive years of record revenue.
InfuSystem Reports Seventh Consecutive Year of Record Net Revenues of $143.4M, Net Income Up 183%
Full year net revenues $143.4 million, a 6% increase over prior year.
InfuSystem to report Q4/FY2025 preliminary results on Feb 24, 2026
Company will issue preliminary Q4 and full-year 2025 results before market open on Tuesday, February 24, 2026.
InfuSystem gets CMS separate payment for two pain pumps under NOPAIN Act starting Jan 2026
CMS added CADD-Solis (ICU Medical) and Sapphire (Eitan Medical) pumps to qualifying list for separate payment.
InfuSystem TTM revenue $141.1M, AEBITDA $30.2M; guides 6-8% FY2025 growth
TTM revenue through Sep 30, 2025: $141.1M; estimated 2025 revenue grows 6-8% over 2024's $134.9M.
InfuSystem CEO and CFO to attend Craig-Hallum conference Nov 18
Carrie Lachance (CEO) and Barry Steele (CFO) will participate in the 16th Annual Craig-Hallum Alpha Select Conference.
InfuSystem Q3 2025 revenue $36.5M (+3% YoY), net income $2.3M (+25%), reaffirms 2025 guidance
Net revenues $36.5M (record), up 3% vs. $35.3M a year ago; Patient Services up 8%, Device Solutions down 3%.
InfuSystem announces Q3 2025 earnings release and call on Nov. 4
Q3 2025 financial results to be issued before market open on November 4, 2025.
InfuSystem updates TTM revenue to ~$140M, adj EBITDA ~$30M; net leverage 0.86x
TTM 6/30/25 net revenue ~$140M, up from $134.9M in FY2024; adjusted EBITDA ~$30M vs. $25.3M.
InfuSystem CEO and CFO to present at ROTH Healthcare Conference on Oct 9
Carrie Lachance (CEO) and Barry Steele (CFO) present at 4th Annual ROTH Healthcare Opportunities Conference.
Net revenue $36.0M (+7% YoY); Patient Services $21.5M (+6%), Device Solutions $14.5M (+8%).
InfuSystem to report Q2 2025 results on Aug 5 before market open
Q2 2025 earnings release scheduled for August 5, 2025 before market open.
InfuSystem extends credit agreement maturity to July 15, 2030
Second Amendment to Credit Agreement with JPMorgan as agent extends maturity to July 15, 2030.
Base salary $500,000; annual bonus up to 100% of base based on performance targets set by Compensation Committee.
InfuSystem shareholders approve equity plan increase to 6M shares; Board elects Hundzinski Chairman
Stockholders approved Second Amendment to 2021 Equity Plan, increasing reserved shares to 6,000,000 from prior limit.
InfuSystem provides FY2025 outlook: 8-10% revenue growth, high-teens AEBITDA margin
TTM revenue to March 31, 2025: $137.6M; TTM adj. EBITDA $27.8M (leverage 0.98x).
InfuSystem Q1 revenue $34.7M (+9% YoY); Adj. EBITDA $6.3M (+64%)
Net revenue $34.7M (+9% YoY); net loss narrowed to $0.3M ($0.01 loss per share) from $1.1M.
InfuSystem to report Q1 2025 results on May 8; conference call same day
InfuSystem (INFU) will issue Q1 2025 financial results on May 8, 2025 before market open.
InfuSystem CEO Richard DiIorio to step down; Carrie Lachance named new CEO effective May 19, 2025
Richard DiIorio to step down as CEO effective May 19, 2025; separation not due to any disagreement with the Company.
Q4 net revenues $33.8M (+7% YoY); net income $0.9M ($0.04 EPS) vs $0.1M prior year.
InfuSystem to announce Q4 and FY2024 earnings on March 4, 2025
Preliminary Q4 and full year 2024 results to be issued before market open on March 4, 2025.
InfuSystem provides 2024 guidance: revenue ~$134.2M, adjusted EBITDA ~$26.5M
TTM revenue through 9/30/24 $132.8M; estimated FY2024 revenue $134.2M (high single-digit growth).
InfuSystem to present at Sidoti Small Cap Virtual Conference on Dec 4, 2024
CEO Richard DiIorio, CFO Barry Steele, and President/COO Carrie Lachance will present.
InfuSystem appoints Ron Hundzinski as independent director effective Nov 12, 2024
Board expanded from 7 to 8 members; Hundzinski fills the new seat.
InfuSystem reports record Q3 revenue of $35.3M, up 11% YoY; net income +162%
Net revenue $35.3M (+11% YoY); Patient Services $20.8M (+8%), Device Solutions $14.5M (+15%).
InfuSystem to report Q3 2024 results on Nov 7; conference call at 9 AM ET
Q3 2024 financial results to be released before market open on Thursday, November 7, 2024.
InfuSystem to participate in Lytham Partners Fall 2024 Conference on Oct 1
CEO Richard DiIorio, President Carrie Lachance, CFO Barry Steele will attend conference on October 1, 2024.
InfuSystem releases updated 2024 outlook: revenue ~$134.2M, Adj. EBITDA ~$26.5M
2024 estimated net revenue of $134.2M (+6.7% YoY); Adj. EBITDA $26.5M (high-teens margin).
SI Technologies, a 50/50 JV between InfuSystem and Sanara, will be exclusive US distributor of ChemoMouthpiece's FDA 510(k)-cleared oral mucositis device.
InfuSystem to present at Lake Street BIG8 Conference on Sept 12, 2024
CEO Richard DiIorio and CFO Barry Steele will attend the conference.
Net revenues $33.7M (+6% YoY); net income $0.7M ($0.03 diluted EPS) vs $0.4M ($0.02) prior year.
InfuSystem signs 3-year distribution pact with Smith+Nephew for NPWT system
Three-year agreement to distribute Smith+Nephew's RENASYS EDGE negative pressure wound therapy system.
InfuSystem announces Q2 2024 earnings release and conference call for August 8, 2024
Q2 2024 financial results to be released before market open on August 8, 2024.
InfuSystem projects 2024 revenue of $134.2M and adjusted EBITDA of $26.5M
2023 revenue $125.8M (12% CAGR over 5 years); adjusted EBITDA $22.4M.
InfuSystem to present at Sidoti Small Cap Conference on June 12, 2024
CEO Richard DiIorio, CFO Barry Steele, and President Carrie Lachance will present.
InfuSystem authorizes $20M stock buyback through June 2026, replacing expiring program
Board approved repurchase of up to $20M of common stock through June 30, 2026.
Proposal 1: All seven board nominees elected, each receiving >9.8M for votes (broker non-votes 2.4M).
InfuSystem reports Q1 revenue up 5% to $32.0M; net loss widens, reaffirms guidance
Net revenues of $32.0M (+5% YoY); record quarterly revenue.
InfuSystem to report Q1 2024 earnings on May 9, 2024 before market open
First quarter 2024 financial results to be released on Thursday, May 9, 2024 before market opens.
InfuSystem warned by NYSE American for failing to file 2023 10-K on time
Received NYSE American non-compliance notice due to failure to file 2023 Annual Report by April 1, 2024.
FY2023 net revenue $125.8M (+14% YoY); Patient Services $76.5M (+11%), Device Solutions $49.2M (+20%).
InfuSystem to report Q4 and FY2023 preliminary results on March 14, 2024
Preliminary Q4 and full-year 2023 financial results to be issued before market open on Thursday, March 14, 2024.
Director Malhotra resigns from InfuSystem Board; company pays $625K under cooperation pact
R. Rimmy Malhotra resigned from the Board effective March 8, 2024; no disagreement cited.
the newly constituted Board of Directors elected Beverly Huss to serve as the Chairman of the Board of Directors.
The Second Amended Agreement reflects changes in Ms. Lachance’s compensation and other terms of employment in connection with her previously announced transition from President and Chief Operating Officer of the Company to President and Chief Executive Officer of the Company that occurred on May 19, 2025.
Following the Annual Meeting, the newly constituted Board of Directors elected Ronald Hundzinski to serve as the Chairman of the Board of Directors and disbanded the role of Executive Chairman.
Coincident to Ms. Lachance's appointment, Scott Shuda was appointed Executive Chairman of the Company's Board.
The Board has appointed Carrie Lachance as the new CEO, effective as of the Separation Date.
Mr. DiIorio will step down as the Company's Chief Executive Officer ("CEO"), effective May 19, 2025
will continue to serve on the Board until the end of his term, which expires May 15, 2025
elected Ron Hundzinski to fill the vacancy created by this increase in size of the Board of Directors.
accepted the resignation of Mr. R. Rimmy Malhotra as a member of the Board, effective March 8, 2024
On March 24, 2023 , Christopher Sansone notified InfuSystem Holdings, Inc. (the “Company”) of his decision not to stand for re-election to the Board of Directors
On September 20, 2022 , the Board of Directors of InfuSystem Holdings, Inc. (the “Company”) expanded the size of the Board of Directors from seven to eight members and elected R. Rimmy Malhotra to fill the vacancy created by this increase in size of the Board of Directors.
Max materiality 0.90 · Median 0.55 · Most common event other_material